Creating Impact Together

Progress is built on collective contributions.

Ichnos Sciences welcomes collaboration with partners that have bold ideas and capabilities that complement and stretch our potential to shift progress, advance science, and deliver transformative medicines. 

Oncology Pipeline and the BEAT® Platform Partnerships

Ichnos is committed to advancing our clinical-stage oncology portfolio and the next wave of discovery-stage assets. We are looking for joint development partners in preclinical and clinical stages who have expertise in immuno-oncology and are interested in collaborating with us as we work to bring multispecific antibodies to patients with hematologic cancers and solid tumors.

Our BEAT® platform enables deep exploration of the bi/multispecific design space to optimize drug candidates and unlock new biology (e.g., T-cell, NK cells, macrophage engagers). Features include:

  • Heavy chain pairing technology
  • Heavy/light chain pairing technology using a common light chain
  • Effective target affinity maturation
  • Efficient purification, 95% yield in a single purification step with BEAT® 2.0
  • Flexible platform enables exploration of the full design space
  • Fc function activity can be modulated (T-cell: silent; non T-cell: active – enhanced)

Interested in partnering?  Contact us at Corporate.Communications@IchnosSciences.com

Autoimmune Disease Partnerships

Ichnos is out-licensing two assets that were developed to treat a range of autoimmune diseases with high unmet need.

Asset / MOA Status Licensee
  • ISB 880 / ALM27134
    IL-1RAP antagonist antibody
  • Out-licensed in December 2021
  • Ready to start Phase 1, IND filing planned in first half of 2022
  • ISB 830 (telazorlimab)
    OX40 antagonist
  • Successfully completed a Phase 2b study in atopic dermatitis
  • U.S. IND for RA and other autoimmune indications is active
  • Out-licensing discussions ongoing

View Career Opportunities

Career Opportunities

The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.